Brakiva (topotecan liposomal) / Assertio - LARVOL DELTA

Third-line chemotherapy for NSCLC confers clinically meaningful PFS to immunotherapy-exposed patients (Healio) - P=NA, N=43; "Patients with non-small cell lung cancer exposed to immunotherapy as second-line treatment achieved clinically meaningful PFS after receiving chemotherapy in the third-line setting, according to study results presented at HOPA Ahead 2019...The most common third-line chemotherapy regimens included docetaxel (58.1%), platinum (18.6%), gemcitabine (7%) or pemetrexed (7%). Other regimens included albumin-bound paclitaxel, vinorelbine, topotecan and osimertinib (Tagrisso, AstraZeneca)....An analysis of outcomes based on type of third-line chemotherapy showed patients treated with a platinum regimen achieved longer median PFS (242 days vs. 117 days with docetaxel and 149 for other regimens) and median PFS (625 days vs. 442 days with docetaxel and 452 days with other regimens)..."

Retrospective data

Targeting ovarian cancer (Cure Today) - "'There are never enough treatment options out there for patients {with} ovarian cancer. It is a very difficult disease with a very high risk of cancer coming back. Over 80 percent of ovarian cancers will recur, so we need treatment options out there that actually work,' said Floor J. Backes, M.D…While folate receptors are being tested for the treatment of women with platinum-resistant ovarian cancer, Backes urged individuals to get involved in clinical studies."

Media quote